ClinicalTrials.gg
Enrolling by invitationNCT07102849Updated Oct 15, 2026

Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study

An observational study in Bone Marrow Failure Disorders, VEXAS Syndrome and Hemoglobinurea, Paroxysmal, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Enrolling by invitation at 1 site in United States. Open to participants aged 2 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
1,400
Ages
2 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Bone Marrow Failure Disorders with a site in United States — 21 open to participants now, 29 under way, none of them phase 3. Bone Marrow Failure Disorders · United States.

Planned enrollment
3rd of 10
1,400 · median 325
Started
2025
with 3 others
Observational
10 of 67
5 open now
Primary completion
2030-07
later than 21 of 28 live
Registered
61st of 67
by date
Lead sponsor
9 of 67
National Heart, Lung, and Blood Institute (NHLBI)

Among the 67 studies in Bone Marrow Failure Disorders with a site in United States, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2025, is one of 10 observational ones, reaches primary completion later than 21 of the 28 other live ones, and was the 61st registered.

Bone Marrow Failure Disorders

91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.

Browse Bone Marrow Failure Disorders studies →

Open to participants now

21 of the 67 studies in Bone Marrow Failure Disorders with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Bone Marrow Failure Disorders studies recruiting now, 9 (39%) set no upper age limit and 12 (52%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Bone Marrow Failure Disorders with a site in United States, or all of them as a file.
02

Study summary

STUDY DESCRIPTION:

Bone marrow failure can result from immune mediated attack on stem cells or from inherited genetic defects such as telomere biology disorders or Fanconi anemia. Aplastic anemia (AA), a prototype of bone marrow failure syndromes (BMFS), can be acquired or inherited. Acquired BMFS have common immune mediated pathophysiology, and include AA, lower risk myelodysplastic syndrome (MDS, particularly hypoMDS), VEXAS, large granular lymphocytosis (LGL), paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia (PRCA), or cytopenia of undetermined origin. Clonality is frequent in patients with BMFS. Patients with acquired AA are known to have somatic mutations in phosphatidylinositol glycan class A (PIGA), BCL6 corepressor (BCOR) and HLA genes, which are all related to the immune mediated pathophysiology and good predictors of treatment and overall outcomes. Others such as ASXL1, RUNX1, and splicing factor mutations and/or chromosome 7 aneuploidy are associated with secondary myeloid neoplasms in these patients. Somatic mutations in STAT, DNMT3A and TET2 are prevalent in many other BMFS, such as LGL and VEXAS. Except for acquired AA, the clonal dynamics and trajectories, and cooccurrence of these aberrations in other BMFS are poorly understood. How these clonal events interact with epigenetic and proteomic changes are also unknown. In addition, the role of novel genetic defects in marrow failure is poorly characterized, such as mutations associated with inborn errors of immunity or complement pathways. Our aim is to elucidate this further using multi-omics, bulk/single cell DNA and RNA techniques as well as understand the epigenetics using ATAC-seq, and proteomics. The translation work will be correlated with clinical outcomes and laboratory parameters of patients with the particular BMFS cohort being investigated.

OBJECTIVES:

Primary Objective: To characterize the molecular aberrations in BMFS and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of hematopoietic stem and progenitor cells (HSPC), immune cells and other cellular composition in peripheral blood and bone marrow samples.

Secondary Objectives:

  • To correlate the molecular findings with disease presentation and clinical outcomes (response to treatment, clonal evolution to secondary myeloid neoplasm, survival)
  • To correlate molecular findings with clinical laboratory data, cytokine, chemokine, soluble receptor levels and growth factors
  • To correlate findings with peripheral or marrow flow cytometry phenotyping
  • To correlate findings on this study with already performed germline or somatic mutational data
  • To compare the genomic, epigenomic and proteomic findings with healthy age matched controls
Read the detailed description

STUDY DESCRIPTION:

Bone marrow failure can result from immune mediated attack on stem cells or from inherited genetic defects such as telomere biology disorders or Fanconi anemia. Aplastic anemia (AA), a prototype of bone marrow failure syndromes (BMFS), can be acquired or inherited. Acquired BMFS have common immune mediated pathophysiology, and include AA, lower risk myelodysplastic syndrome (MDS, particularly hypoMDS), VEXAS, large granular lymphocytosis (LGL), paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia (PRCA), or cytopenia of undetermined origin. Clonality is frequent in patients with BMFS. Patients with acquired AA are known to have somatic mutations in phosphatidylinositol glycan class A (PIGA), BCL6 corepressor (BCOR) and HLA genes, which are all related to the immune mediated pathophysiology and good predictors of treatment and overall outcomes. Others such as ASXL1, RUNX1, and splicing factor mutations and/or chromosome 7 aneuploidy are associated with secondary myeloid neoplasms in these patients. Somatic mutations in STAT, DNMT3A and TET2 are prevalent in many other BMFS, such as LGL and VEXAS. Except for acquired AA, the clonal dynamics and trajectories, and cooccurrence of these aberrations in other BMFS are poorly understood. How these clonal events interact with epigenetic and proteomic changes are also unknown. In addition, the role of novel genetic defects in marrow failure is poorly characterized, such as mutations associated with inborn errors of immunity or complement pathways. Our aim is to elucidate this further using multi-omics, bulk/single cell DNA and RNA techniques as well as understand the epigenetics using ATAC-seq, and proteomics. The translation work will be correlated with clinical outcomes and laboratory parameters of patients with the particular BMFS cohort being investigated.

OBJECTIVES:

Primary Objective: To characterize the molecular aberrations in BMFS and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of hematopoietic stem and progenitor cells (HSPC), immune cells and other cellular composition in peripheral blood and bone marrow samples.

Secondary Objectives:

  • To correlate the molecular findings with disease presentation and clinical outcomes (response to treatment, clonal evolution to secondary myeloid neoplasm, survival)
  • To correlate molecular findings with clinical laboratory data, cytokine, chemokine, soluble receptor levels and growth factors
  • To correlate findings with peripheral or marrow flow cytometry phenotyping
  • To correlate findings on this study with already performed germline or somatic mutational data
  • To compare the genomic, epigenomic and proteomic findings with healthy age matched controls
03

Conditions studied

  • Bone Marrow Failure Disorders
  • VEXAS Syndrome
  • Hemoglobinurea, Paroxysmal
  • Myelodysplastic Syndromes
  • Bone Marrow Diseases

Keywords

  • Bone Marrow Failure
  • Aplastic Anemia
  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
2 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will utilize biospecimens and data with identifiers from up to 1,400 research participants with BMFS, aged 2 years and older, alongside age matched healthy volunteers aged 8 years and older.

Eligibility criteria

  • This study will utilize biospecimens and data with identifiers from up to 1,400 research participants with BMFS, aged 2 years and older, alongside age matched healthy volunteers aged 8 years and older.
05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
1,400 participants (estimated)

Groups and cohorts

  • Healthy Volunteers

    Biospecimens and data from age matched healthy volunteers (age 8 and up) will be used from the following protocol:- 07H0113 Procurement and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers to Support Clinical and Translational Research Projects in the NHLBI.

  • Participants with Bone Marrow Failure Disorders

    Biospecimens and data from children and adults with BMFS who participated in the following studies will be used:- 04H0012 "Collection of Tissue Specimens from Patients with Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members"Clinical and research data from children and adults with BMFS who participated in the following studies will be used:- 06H0034 "Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia"- 12H0150 "Eltrombopag with Standard Immunosuppression for Severe Aplastic Anemia"- 20H0033 "Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)"- 09H0154 "A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag, in Refractory Aplastic Anemia Patients"

06

What researchers measure

Primary outcomes

  1. Detection of molecular aberrations in marrow failure

    To characterize the molecular aberrations in marrow failure and to understand how clonality, epigenetics, and proteomics contribute to hematopoiesis over the course of disease using high resolution multi-omics characterization of HSPC, immune cells and other cellular composition in peripheral blood and bone marrow samples.

    Time frame: baseline

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2030, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2025
First posted
Aug 5, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Jul 11, 2030
CompletionEst.
Jul 11, 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07102849
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Sep 9, 2025
Primary completion
Jul 11, 2030 (estimated)
Completion
Jul 11, 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Bhavisha A Patel, M.D.
principal investigator · National Heart, Lung, and Blood Institute (NHLBI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion